Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shalom Lerrer"'
Autor:
Sabina Sandigursky, Adam Mor, Johanna Straube, Marianne Strazza, Kieran Adam, Shalom Lerrer, Beatrix Ueberheide
Publikováno v:
Inflammation
PD-1 is a critical therapeutic target in cancer immunotherapy and antibodies blocking PD-1 are approved for multiple types of malignancies. The phosphatase SHP2 is the main effector mediating PD-1 downstream signaling and accordingly attempts have be
Autor:
Elliot A. Philips, Benjamin G. Neel, Beatrix Ueberheide, Kieran Adam, Anna S. Tocheva, Marianne Strazza, Adam Mor, Inbar Azoulay-Alfaguter, Shalom Lerrer, Connor Foster, Michael Peled, Shruti Nayak
Publikováno v:
The Journal of Biological Chemistry
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell–mediated anti-t
Autor:
Adam Mor, Shalom Lerrer
Publikováno v:
Transl Cancer Res
Checkpoints are inhibitory receptors expressed on activated T cells. During the process of carcinogenesis, tumor cells progressively express multiple inhibitory receptor-ligands to prevent T cell recognition and elimination. Consequently, therapeutic
Publikováno v:
Curr Protoc Immunol
Our understanding of programmed cell death 1 (PD-1) biology is limited due to technical difficulties in establishing reproducible, yet simple, in vitro assays to study PD-1 signaling in primary human T cells. The protocols in this article were refine
Publikováno v:
Clin Exp Immunol
Summary Phospholipase C epsilon 1 (PLCε1) is a unique member of the phospholipase family, in that it also functions as a guanine nucleotide exchange factor (GEF) for the small GTPase Rap1. It is this function as a Rap1 GEF that gives PLCε1 an essen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21562db2445e4e115dd57be5917fad12
https://europepmc.org/articles/PMC7066383/
https://europepmc.org/articles/PMC7066383/
Autor:
Adit Ben-Baruch, Agnes Hotz-Wagenblatt, Stefan Wiemann, Alexander Bott, Shalom Lerrer, Khalid Abnaof, Heike Wilhelm, Christian Breunig, Angelika Wörner, Nese Erdem, Ewald Münstermann
Publikováno v:
Oncotarget
// Alexander Bott 1 , Nese Erdem 1 , Shalom Lerrer 2 , Agnes Hotz-Wagenblatt 3 , Christian Breunig 1 , Khalid Abnaof 1 , Angelika Worner 1 , Heike Wilhelm 1 , Ewald Munstermann 1 , Adit Ben-Baruch 2 and Stefan Wiemann 1 1 Division of Molecular Genome
Autor:
Cindy Körner, Yulia Liubomirski, Shalom Lerrer, Linor Rubinstein-Achiasaf, Stefan Wiemann, Tsipi Meshel, Adit Ben-Baruch, Dina Morein
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology
Frontiers in Immunology
The tumor microenvironment (TME) plays key roles in promoting disease progression in the aggressive triple-negative subtype of breast cancer (TNBC; Basal/Basal-like). Here, we took an integrative approach and determined the impact of tumor-stroma-inf
Autor:
Dina Morein, Cindy Körner, Linor Rubinstein-Achiasaf, David Sprinzak, Tsipi Meshel, Marcelo Ehrlich, Yulia Liubomirski, Adit Ben-Baruch, Stefan Wiemann, Shalom Lerrer
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Stromal cells and pro-inflammatory cytokines play key roles in promoting the aggressiveness of triple-negative breast cancers (TNBC; Basal/Basal-like). In our previous study we demonstrated that stimulation of TNBC and mesenchymal stem cells (MSCs) c
Autor:
Yulia Liubomirski, Cindy Körner, Shalom Lerrer, Alexander Bott, Tsipi Meshel, Adit Ben-Baruch, Stefan Wiemann, Nino Oren, Afsheen Yousaf, Khalid Abnaof
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Frontiers in Immunology
Frontiers in Immunology
High plasticity is a hallmark of mesenchymal stem cells (MSCs), and as such, their differentiation and activities may be shaped by factors of their microenvironment. Bones, tumors, and cardiomyopathy are examples of niches and conditions that contain